Daily Programme

Saturday, 1 November 2014


Symposia Sessions

The following Symposia sessions will take place on Saturday, 1 November 2014.

Please click here to download all symposia as one PDF.


Title of symposium




Saturday, 1 November 2014 - 09:15 - 11:15

37. TB/HIV Late-breaker session (TBC) TBC TBC 112
38. Progress and lessons learnt from national TB prevalence surveys Tuberculosis Ikushi Onozaki (Switzerland), 
Marina Tadolini (Italy)
39. Engaging communities of special risk groups in conflict affected communities Tuberculosis Oriol Ramis (Spain), 
Lucie Blok (Netherlands)
40. Tuberculosis infection control and occupational TB among health care workers: a time for action Tuberculosis Carrie Tudor (USA), 
Rose Pray (USA)
41. Moving the next generation of TB diagnostics for drug resistance closer to patients: data sharing TB/Bacteriology and Immunology John Ridderhof (USA), 
Siva Danaviah (South Africa)
42. Emerging perspectives in the treatment of paediatric MDR-TB Adult and Child Lung Health Anneke Hesseling (South Africa), 
James Seddon (UK)
43. Magic bullet? Data-driven insights on the impact of community workers on case detection and treatment outcomes TB/ Nurses and Allied Professionals Ellen H Mitchell (Netherlands) 118/119
44. Zoonotic tuberculosis: a global socio-economic problem TB/ Zoonotic TB Adrian Muwonge (Uganda) 120/121
45. Partnerships: working for community-driven impact to ensure quality care for persons affected by TB Civil Society Thomas Mohr (Kazakhstan), 
Jenniffer Dietrich (Switzerland)

Saturday, 1 November 2014 - 14:00 - 16:00

46. Innovative solutions in surveillance of drug-resistant TB: from phenotypic to molecular testing TB/Bacteriology and Immunology Ananta Nanoo (South Africa), 
Alaine Umubyeyi Nyaruhirira (South Africa)
47. Engaging communities in the fight against TB and HIV Civil Society Mandy Slutsker (USA), 
Alisha Smith-arthur (USA)
48. Multi-faceted regional response to tuberculosis in the mining sector in Southern Africa Tuberculosis Okore Okorafor (South Africa), 
M. thulani Mbatha (South Africa)
49. Developing a roadmap for integration of TB-HIV activities in maternal and child health settings HIV Surbhi Modi (USA), 
Anna Mandalakas (USA)
50. Enhancing TB control with structural interventions: from incentives and enablers to social protection Tuberculosis Delia Boccia (UK), 
Alexander Golubkov (USA)
51. COPD: diagnostic and therapeutic challenges in developing countries Adult and Child Lung Health Jean-William Fitting (Switzerland) 115
52. Reaching the unreached through new civil society initiatives integrating community-based TB activities Civil Society Petra Stankard (USA), 
Thomas Joseph (India)
53. Non-communicable diseases and tobacco control Tobacco Gan Quan (China) 118/119


Abstract Sessions


Sessions Section(s) Chairs
Saturday, 01 November 2014, 12:45-13:45    
45. TB in children: epidemiology ACLH Simon Schaaf (South Africa)
46. Clinical trials: drugs and vaccines BACT. Antonio Catanzaro (USA)
47. TB molecular epidemiology: from laboratory diversity to outbreak BACT. Daniela M Cirillo (Italy)
48. Molecular detection of TB and drug resistance - II BACT. Leen Rigouts (Belgium)
49. Factors affecting access and health seeking behaviour CS Asma El Sony (Sudan)
50. Treatment, management and diagnosis: a potpourri of TB and HIV issues HIV Colleen Daniels (USA)
51. The gamut of training: from patients to professionals NAPS Kedibone Mdolo (South Africa)
52. TB case finding: if you look for it, you will find it TB Alice Christensen (Tanzania)
53. Case finding/LTBI: adults and children TB Beate Kampman (UK)
54. TB in the elderly: effects and outcome TB Austin Arinze Obiefuna (Ghana)
55. TB spatial epidemiology in high-burden settings TB Arnaud Trébucq (France)
56. TB relapses, recurrence and retreatment TB Akira Shimouchi (Japan)
57. TB control TB Roberto Assael (Mexico)
58. MDR-/XDR-TB management: new approaches TB Hans L Rieder (Switzerland)
59. MDR-TB: epidemiology TB Peter Davies (UK)
60. MDR-TB: special locations TB Onn Min Kon (UK)
61. TB information systems: evaluating treatment outcomes TB Abbas Zezai (Namibia)
62. TB in special population: risky places and occupations TB Mary Edginton (South Africa)
63. All smoke free: from government to community TC Vivek Ramesh (India)
64. Tobacco control laws: the force is still with us! TC Mirta Molinari (Mexico)
65. TB prevalence estimations TB Ghislain Koura (France)
66. TB in prisons TB Nii Nortey (Ghana)

Plenary Sessions

Saturday, 1 November 2014

Time: 11:30 - 12:30  Room: Auditorium

"Panel discussion: Community driven solutions: present perspectives and future vision" 

Speakers: Patrick Nsimba Mata, TB advocate, Deputy National Secretary and Project Coordinator for Club des Amis Damien, Democratic Republic of Congo; Edith Garba, lawyer and MDR-TB survivor, Nigeria; Mesake Navugona, rugby league player at 2000 World Cup and former TB patient, Fiji; Oleksandr Kulchenko, Treatment Programmes Support Unit, All-Ukrainian Network of People Living with HIV, Ukraine

Moderators: Oxana Rucsineanu (Moldova), D’Arcy Richardson (USA)


Patrick Nsimba Mata, TB advocate; Deputy National Secretary and Project Coordinator for Club des Amis Damien (Democratic Republic of Congo)


Patrick Nsimba Mata is a former TB patient from the DR Congo, who has been an activist in the fight against TB since 2001. He joined the Club des Amis Damien (CAD) where he took on the role of referring possible TB patients, offering psychosocial support to critically ill patients and providing information to communities. Formerly trained as a mathematician and physicist, he has since completed undergraduate and graduate degrees in international relations. Through this advocacy work, he has also received extensive training in skills from HIV testing and counselling to computer skills.  In 2013, he participated in the external review of the National TB Control Programme. He is the Deputy National Secretary and Project Coordinator for CAD and an Alternate Member of the Global Fund/DRC CCM representing TB patients.

  Edith Garba, lawyer and MDR-TB survivor (Nigeria)


Edith Garba was raised in Kaduna state in northern Nigeria. She attended the Ahmadu Bello University Zaria Nigeria and Nigerian Law School and is a lawyer by profession. She successfully completed her 20-month multi-drug resistant tuberculosis (MDR-TB) treatment without any adverse effects. The testimony of her treatment success is summarised in the poem "MDR-TB Leap". She was an active participant in the National Strategic Plan (NSP) workshop held in Nigeria in November 2013 and is currently a member of the Global Drug-Resistant Initiative (GDI).

  Mesake Navugona, rugby league player at 2000 World Cup and former TB patient (Fiji)


Mesake Navugona comes from Fiji, where he is a plumber by trade and works as a Technical Officer for Fiji’s Water Authority. He has been involved with sports since he was 10 years old and has represented Fiji in soccer, rugby and rugby league. He does a great deal of voluntary work helping the young people with sports and managing the National Rugby League teams at various overseas tournaments. He is a TB survivor and advocate who helps Fiji’s young people through awareness programmes.

  Oleksandr Kulchenko, Treatment Programmes Support Unit, All-Ukrainian Network of People Living with HIV (Ukraine)


Meet the Expert Sessions

Saturday, 1 November 2014 - 08:00- 09:00

Short course treatment for MDR-TB 

Measuring the impact of diagnostic testing

WHO guidelines

MDR-TB treatment

Indoor air pollution and tuberculosis

E-cigarettes: existence of evidence?


The 'Meet the Expert' sessions bring in experts in various fields, to meet with small groups of participants to discuss, face to face, the challenges and opportunities presented by working to promote lung health.

These sessions are free of charge for registered participants only. The number of persons attending each session should not exceed 30.

Registration for the 'Meet the expert' sessions is available on site, at the conference Registration Desk. Participation will be on a first-come, first-served basis.                                

Valérie Schwoebel (France), Arnaud Trébucq (France)
Room: 114


The current 20-month internationally recommended treatment for MDR-TB is very
disappointing with success rates around 60%, and very expensive. In Bangladesh, Van Deun
et al. have shown that it was possible to cure MDR-TB with almost no relapse and no failure
in 9 months. Following this example, 9 countries in Sub-Saharan Africa are participating in
a study on this registration coordinated by the Union. A lot of other countries all over the
world are willing to test this short-course regimen. Reasons and constraints to implement this
regimen will be discussed.

Gavin Churchyard (USA)
Room: 115
There are many studies that have evaluated the performance of diagnostic tests but very few that have evaluated patient, programme and population level impact of TB diagnostics. In this session we will review the pipeline of new TB diagnostics, the need for evaluating the impact of new TB diagnostics, and the pros and cons of various approaches to evaluating the impact of new diagnostics.
Alberto Matteelli (Switzerland)  
Room: 116
Latent tuberculosis infection (LTBI) affects about one-third of the world's population, of which 10% will develop active TB disease in their lifetime. Systematic testing and treatment of LTBI in at-risk populations is a critical component of WHO’s eight-point framework adapted from the post-2015 Global TB Strategy to target pre-elimination and, ultimately, elimination in low incidence countries. Recognizing the importance of expanding the response to LTBI, in 2014 WHO developed Guidelines on the Management of Latent Tuberculosis Infection. In this session, opportunities and challenges of guidelines implementation will be discussed.


Simon Schaaf (South Africa)
Room: 118/119
There is a worldwide increase in awareness of drug-resistant tuberculosis in children. Although the diagnosis remains a challenge, new genotypic diagnostic tests have made confirmation of drug resistance more feasible compared with phenotypic (culture) testing, but the interpretation of these new tests have their own challenges. Treatment with second-line drugs is effective, but the challenge now is optimising dosages and treatment regimens for children  


Chen-Yuan Chiang (Taiwan), Hsien-Ho Lin (Taiwan)                                                                                                   Room: 120/121


The estimated population attributable fraction of indoor air pollution for tuberculosis (TB) in 22 high TB burden countries was substantial (26.2%), implying that reducing exposure to combustion of solid fuels may have considerable impact in global TB control. However, a recent systemic review and meta-analysis reported that the level of evidence for the association between domestic use of solid fuels and TB was very low. High-quality studies are badly needed to clarify this association and to estimate the magnitude of the problem.


Ehsan Latif (UK), Myra Wisotzky (USA)

Room: 122/123


The session will discuss the various challenges posed by e-cigarettes on tobacco control efforts and its relation to the discussions on Non-Communicable Disease control. The experts shall outline the efforts that need to be undertaken to ensure e-cigarettes are properly regulated and their availability monitored both by the governments and civil society.

Union Administrative Meetings





General Assembly



Board Meeting 2



Closing Ceremony



Closing Reception


Side Meetings

Further information on Side-Meetings will be posted as soon as they become available.

Sub-section Meetings




Saturday, 1 November 2014

15:00-16:00 Zoonotic TB 122/123

Technical Exhibition

There will be a Scientific and Technical Exhibition during the conference showcasing a variety of companies, agencies, non-governmental organisations (NGOs), health organisations and manufacturers of materials and equipment.